References
  1. Hekking PP, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol . 2015;135:896-902.
  2. Vianello A, Caminati M, Andretta M, et al. Prevalence of severe asthma according to the drug regulatory agency perspective: an Italian experience. World Allergy Organ J. 2019;12:100032.
  3. Chhiba KD, Patel GB, Vu THT, et al. Prevalence and characterization of asthma in hospitalized and non-hospitalized patients with COVID-19.J Allergy Clin Immunol. 2020. https://doi.org/10.1016/j.jaci.2020.06.010. [Epub ahead of print].
  4. Micheletto C, Bilò MB, Antonicelli L, et al.; and on behalf of IRSA. Severe asthma in adolescents and adults: a national, multicenter registry in real life. Eur Ann Allergy Clin Immunol . 2018;5:196-201.
  5. Department of Civil Protection Coronavirus task force, National and Subregional data repository available on GitHub. https://github.com/pcm-dpc/COVID-19 Accessed June 10, 2020.
  6. Peters MC, Sajuthi S, Deford P, et al.; National Heart, Lung, and Blood Institute Severe Asthma Research Program-3 Investigators. COVID-19 related genes in sputum cells in asthma: relationship to demographic features and corticosteroids. Am J Respir Crit Care Med . 2020. https://doi.org/10.1164/rccm.202003-0821OC” https://doi.org/10.1164/rccm.202003-0821OC. [Epub ahead of print].
  7. Carli G, Cecchi L, Stebbing J, Parronchi P, Farsi A. Is asthma protective against COVID-19? Allergy . 2020. https://doi.org/10.1111/all.14426” https://doi.org/10.1111/all.14426. [Epub ahead of print].
  8. Mahdavinia M, Foster KJ, Jauregui E, et al. Asthma prolongs intubation in COVID-19. J Allergy Clin Immunol Pract . 2020;S2213-2198(20)30476-1. https://doi.org/10.1016/j.jaip.2020.05.006” https://doi.org/10.1016/j.jaip.2020.05.006. In press.
  9. Davies NG, Klepac P, Liu Y, Prem K, Jit M CMMID COVID-19 working group; Eggo RM. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat Med . 2020. https://doi.org/10.1038/s41591-020-0962-9.